The combined effect of mesalazine-crocin in the treatment of inflammatory bowel disease

Phase 3

Recruiting

• Conditions: Condition 1: Crohn's disease. Condition 2: Ulcerative colitis.; Crohn's disease [regional enteritis]; Ulcerative colitis

• Registration Number: IRCT20230511058153N1
• Lead Sponsor: Shahre-kord University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 June 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Inflammatory bowel diseases including Crohn's or ulcerative colitis
Informed consent to participate in the study
No history of other autoimmune diseases
No history of underlying diseases
No use of other medicinal plants
Patients with moderate type Inflammatory bowel diseases
Insensitivity to salicylates
Insensitivity to any of the saffron compounds

Exclusion Criteria

Reluctance to continue participating in the study
Death of the patient
Pregnancy or breastfeeding
In case of any unwanted side effects

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The score of clinical symptoms of colitis in the Partial Mayo score questionnaire. Timepoint: Before the start of the intervention and 8 weeks after the start of the intervention. Method of measurement: Partial Mayo score questionnaire.;The score of the clinical symptoms of Crohn in the Harvey Bradshaw index questionnaire. Timepoint: Before the start of the intervention and 8 weeks after the start of the intervention. Method of measurement: Harvey Bradshaw index questionnaire.